Pharmaceutical wastewater treatment process and treatment device

Abstract

The invention belongs to the technical field of water treatment processes and devices, and particularly relates to a pharmaceutical wastewater treatment process and a pharmaceutical wastewater treatment device. According to the treatment process of the pharmaceutical wastewater, the pharmaceutical wastewater is subjected to the following processes: an electric flocculation process, a catalytic ozonation process, a ceramic membrane separation process and a reverse osmosis process; the membrane aperture of the reverse osmosis process is 0.3-0.4 nm, the transmembrane pressure difference is 2.0-3.0 bar, reverse osmosis desalted fresh water and reverse osmosis strong brine are respectively obtained, the reverse osmosis desalted fresh water directly reaches the standard for reuse, and the reverse osmosis strong brine is returned to the electric flocculation process for repeated treatment. The pharmaceutical wastewater treatment process provided by the invention not only can realize synchronous removal of suspended matters and organic matters, but also can realize desalination and deep purification of pharmaceutical wastewater, and provides a feasible and sustainable solution for pharmaceutical wastewater treatment, and the invention also provides a treatment device thereof.

Description

Technical Field

[0001] The invention belongs to the technical field of water treatment processes and devices, and specifically relates to a pharmaceutical wastewater treatment process and a treatment device. Background Art

[0002] With the vigorous development of the pharmaceutical industry, the treatment of pharmaceutical wastewater has become increasingly prominent and has become the focus of social attention. Pharmaceutical wastewater not only contains high concentrations of organic pollutants, but is also rich in inorganic salts, such as sulfates, chlorides, sodium salts, etc. The presence of these inorganic salts significantly increases the total dissolved solids (TDS) content of wastewater, posing severe challenges to the environment and subsequent wastewater treatment processes. The removal of inorganic salts has become a technical problem in the treatment of pharmaceutical wastewater. Due to their high solubility characteristics, traditional physical or biological treatment methods are often difficult to effectively remove them. At the same time, the presence of salts will inhibit the activity of microorganisms and reduce the efficiency of the biological treatment system.

[0003] At present, although there are various treatment technologies for pharmaceutical wastewater, each has certain limitations. As an electrochemical method, electrocoagulation can effectively remove suspended solids, colloidal substances and organic matter in water, and achieve the coagulation and precipitation of pollutants through various mechanisms such as electrochemical reactions, mass transfer processes and flotation. However, the electrocoagulation process has limited effect in treating inorganic salts and still needs to be used in combination with other technologies to achieve deep purification.

[0004] Catalytic ozone oxidation technology uses catalysts to enhance the efficiency of ozone oxidation reactions, and can effectively degrade organic matter, micropollutants and difficult-to-degrade substances in water. However, when treating complex environments such as pharmaceutical wastewater, a single catalytic ozone oxidation technology often fails to achieve the desired treatment effect, especially when the wastewater contains a large amount of suspended solids (SS), which will inhibit the ozone catalytic oxidation process and reduce the treatment efficiency.

[0005] The ceramic membrane filtration process removes suspended matter, colloids, bacteria, viruses and other tiny particles in water through microporous membranes, and has a high separation efficiency. However, ceramic membrane filtration is usually used as a subsequent treatment unit and requires pre-processing to reduce the content of suspended matter and organic matter, so as to improve filtration efficiency and extend the service life of the membrane.

[0006] The reverse osmosis desalination process uses the principle of selective permeability of semipermeable membranes to remove dissolved salts, colloids, bacteria and organic matter in water, and is an effective means of achieving wastewater desalination. However, the reverse osmosis membrane has high requirements for the quality of the influent water, and requires pre-process pretreatment to remove impurities such as suspended solids and organic matter to avoid membrane pollution and reduce operating costs.

[0007] In order to overcome the shortcomings of existing technologies, researchers have developed a variety of coupled water treatment technologies to treat pharmaceutical wastewater. For example, although the multi-stage nanofiltration process coupled with microbial treatment technology can achieve wastewater desalination, it is affected by organic pollution and cannot achieve long-term and stable desalination effects. Although the multi-terminal coupling process can achieve the effects of desalination and oxidation at the same time, the process flow is cumbersome and the construction cost is high, which is not conducive to practical application.

[0008] In order to solve the desalination problem of pharmaceutical tail water, researchers have developed a variety of coupled water treatment technologies. Patent CN220149414U uses a multi-stage nanofiltration process coupled with microbial treatment to achieve wastewater desalination, but in addition to salts, pharmaceutical tail water often contains a large amount of organic matter, which is an important cause of membrane pollution. This technology cannot achieve long-term and stable desalination effects. Patent CN116693105A uses a multi-terminal coupling process to desalinate and oxidize high-salt and high-concentration organic wastewater. The specific process flow is water inlet-sand settling tank-pre-precipitation oxidation tank-A / A / O tank-secondary settling tank-electrocatalytic tank-electrodialysis device-disinfection oxidation tank-outlet. Although this process can achieve the effects of desalination and oxidation at the same time, the process flow is cumbersome and the construction cost is high, which is not conducive to practical application. Patent CN115215492A mentions an electro-flocculation-ozone catalytic oxidation-ceramic membrane coupled water treatment technology for the removal of residual drugs in pharmaceutical wastewater. However, it lacks the design of the electro-flocculation catalytic ozone oxidation reactor and the systematic optimization of various process parameters, which limits the treatment efficiency. Summary of the invention

[0009] The technical problem to be solved by the present invention is to overcome the above-mentioned defects of the prior art and provide a treatment process for pharmaceutical wastewater, which can not only realize the simultaneous removal of suspended matter and organic matter, but also realize the desalination and deep purification of pharmaceutical wastewater, thereby providing a feasible and sustainable solution for pharmaceutical wastewater treatment. The present invention also provides a treatment device thereof.

[0010] The pharmaceutical wastewater treatment process of the present invention: the pharmaceutical wastewater is subjected to the following processes: electrocoagulation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process; The reverse osmosis process membrane has a pore size of 0.3-0.4 nm and a transmembrane pressure difference of 2.0-3.0 bar, and reverse osmosis desalinated fresh water and reverse osmosis concentrated brine are obtained respectively, wherein the reverse osmosis desalinated fresh water is directly reused up to the standard, and the reverse osmosis concentrated brine is returned to the electro-flocculation process for repeated treatment.

[0011] The parameters of the electrocoagulation process are as follows: the anode is aluminum sheet, iron sheet or zinc sheet, the cathode is a corresponding metal electrode of the same type, the number of electrode pairs is 10, the electrode plate spacing is 1.5~3.5cm, the plates are vertical and placed parallel to each other, and the current density is controlled at 10~20mA / cm 2. Reasonably select the anode and cathode materials according to the actual water quality of pharmaceutical tail water.

[0012] The parameters of the ozone catalytic oxidation process are: ozone concentration 40-60 mg / L, catalyst filling rate 10-30%, contact time 30-120 min, and the catalyst is activated carbon or metal oxide. Ozone catalytic oxidation can effectively decompose organic pollutants and difficult-to-degrade substances in pharmaceutical tail water, and further improve the desalination efficiency of subsequent ceramic membrane process and reverse osmosis process. The "contact time" refers to the duration of contact between wastewater and catalyst.

[0013] The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 40-50 nm, the cross-flow velocity is 200-500 mL / min, the transmembrane pressure difference is 0.1-0.3 bar, the pressure difference drives water to pass through the membrane pores, and salt and other soluble organic matter are retained on the membrane surface.

[0014] The initial SS of the pharmaceutical wastewater is 102-148 mg / L, the initial COD is 212-230 mg / L, the total dissolved solids is 3800-4400 mg / L, when the ozone concentration is controlled at 40 mg / L, the catalyst filling rate is 10%, and the current density is 5 mA / cm 2 When the electro-flocculation-catalytic ozone oxidation-ceramic membrane-reverse osmosis process was run for 30 minutes, the removal rates of SS, COD and total dissolved solids were 88.6-99%, 49.1-59.9% and 77.1-89.5 respectively.

[0015] The pharmaceutical wastewater treatment device comprises an integrated electro-flocculation-ozone catalytic oxidation device, wherein two electrode sheets are arranged inside the integrated electro-flocculation-ozone catalytic oxidation device, and the bottom of the integrated electro-flocculation-ozone catalytic oxidation device is an ozone generator, and a catalyst supporting layer is arranged inside the integrated electro-flocculation-ozone catalytic oxidation device, and the catalyst supporting layer serves to support the catalyst, and its material is the same as the main structure of the integrated electro-flocculation-ozone catalytic oxidation device or other materials that are not affected by temperature and acidity and alkalinity.

[0016] The sewage inlet of the electric flocculation-ozonation catalytic oxidation integrated device is connected with a grid, the grid is connected to a grit chamber, the grit chamber is connected to a primary sedimentation tank, the primary sedimentation tank is connected to a biochemical tank, the biochemical tank is connected to a secondary sedimentation tank, and the secondary sedimentation tank is connected to the electric flocculation-ozonation catalytic oxidation integrated device.

[0017] The water outlet of the electric flocculation-ozone catalytic oxidation integrated device is connected with a ceramic membrane filter device, the ceramic membrane filter device is connected with a reverse osmosis device, and the reverse osmosis device is connected with a disinfection tank.

[0018] The top of the electric flocculation-ozone catalytic oxidation integrated device is provided with an air outlet, and the electrode sheet is connected to a power source through a wire.

[0019] A water outlet and a mud outlet are arranged on the body of the electric flocculation-ozone catalytic oxidation integrated device between the ozone generator and the catalyst supporting layer.

[0020] When the above pharmaceutical wastewater treatment device is used, the pharmaceutical wastewater is mainly treated through the grid-sand settling tank-primary sedimentation tank-biochemical tank-secondary sedimentation tank-electrocoagulation-catalytic ozone oxidation-ceramic membrane-reverse osmosis process-disinfection-water outlet. The present invention systematically designs the design of the electrocoagulation catalytic ozone oxidation reactor and optimizes the process parameters. According to the treatment characteristics of pharmaceutical wastewater, the electrocoagulation ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process is proposed. Compared with the electrocoagulation-ozone catalytic oxidation-ceramic membrane coupled water treatment technology, the reverse osmosis process is added. This is proposed from the perspective of the actual water quality characteristics and treatment efficiency of pharmaceutical wastewater.

[0021] The combined process of electro-flocculation-ozone catalytic oxidation-ceramic membrane-reverse osmosis proposed in the present invention provides an efficient, energy-saving and environmentally friendly treatment scheme for the high salt content, high organic content and complex components of pharmaceutical tail water. The present invention first uses the electro-flocculation process to use the electric field to condense the suspended matter and colloidal particles in the wastewater into larger flocs, which is convenient for subsequent treatment. Then, the catalytic ozone oxidation technology is used to use the strong oxidizing property of ozone to decompose the organic matter in the wastewater that is difficult to biodegrade. At the same time, ozone can react more efficiently under the action of the catalyst to improve the treatment efficiency. Subsequently, the ceramic membrane filtration technology is used to effectively intercept the suspended matter, colloid and some microorganisms in the wastewater to ensure the stability of the effluent water quality. The ceramic membrane has the advantages of corrosion resistance, high temperature resistance, high mechanical strength and long service life, and is suitable for the treatment of pharmaceutical tail water. Finally, the reverse osmosis technology is used to further remove the salt and small molecular organic matter in the water to obtain desalted water that meets the industrial water standards.

[0022] This technology can not only effectively reduce the salt and organic pollutants in pharmaceutical tail water, but also reduce the use of chemical agents during the treatment process, reducing the risk of secondary pollution. In addition, the modular design of this technology makes the system easy to expand and maintain, suitable for pharmaceutical companies of different sizes, and has good market application prospects and promotion value. Through the implementation of the present invention, the water resource recycling rate in the pharmaceutical industry can be significantly improved, promoting green and sustainable development.

[0023] Compared with the prior art, the present invention has the following beneficial effects: (1) The pharmaceutical wastewater treatment process of the present invention can enhance the in-situ removal of suspended matter in water by producing floccules through the electro-flocculation process, thereby reducing the negative impact of the suspended matter on subsequent treatment units.

[0024] (2) In the pharmaceutical wastewater treatment process of the present invention, the aluminum, iron and zinc polyhydroxy oxides produced at the anode can catalyze the decomposition of ozone to produce •OH, promote the oxidative degradation of difficult-to-degrade organic pollutants, and create favorable conditions for subsequent desalination.

[0025] (3) The pharmaceutical wastewater treatment device of the present invention, combined with ceramic membrane and reverse osmosis technology, can further remove substances such as tiny particles, colloids and bacteria, and achieve efficient separation and removal of salt and other dissolved substances in pharmaceutical tail water. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 It is a schematic diagram of the pharmaceutical wastewater treatment device of the present invention.

[0027] In the figure: 1. grid; 2. grit chamber; 3. primary sedimentation tank; 4. biochemical tank; 5. secondary sedimentation tank; 6. electrode; 7. water outlet; 8. power supply; 9. air outlet; 10. integrated electrocoagulation-ozone catalytic oxidation device; 11. sludge outlet; 12. catalyst; 13. catalyst supporting layer; 14. ozone generator; 15. ceramic membrane filtration device; 16. reverse osmosis device; 17. disinfection tank. DETAILED DESCRIPTION

[0028] The present invention will be further described below in conjunction with specific embodiments.

[0029] The devices used in the following embodiments are as follows: Figure 1 As shown, it includes an integrated electro-flocculation-ozone catalytic oxidation device 10, two electrode sheets 6 are arranged inside the integrated electro-flocculation-ozone catalytic oxidation device 10, the bottom of the integrated electro-flocculation-ozone catalytic oxidation device 10 is an ozone generator 14, and a catalyst supporting layer 13 is arranged inside the integrated electro-flocculation-ozone catalytic oxidation device 10.

[0030] The sewage inlet of the integrated electro-flocculation-ozone catalytic oxidation device 10 is connected to a grid 1, the grid 1 is connected to a grit tank 2, the grit tank 2 is connected to a primary sedimentation tank 3, the primary sedimentation tank 3 is connected to a biochemical tank 4, the biochemical tank 4 is connected to a secondary sedimentation tank 5, and the secondary sedimentation tank 5 is connected to the integrated electro-flocculation-ozone catalytic oxidation device 10.

[0031] The water outlet of the integrated electro-flocculation-ozone catalytic oxidation device 10 is connected to a ceramic membrane filter device 15 , the ceramic membrane filter device 15 is connected to a reverse osmosis device 16 , and the reverse osmosis device ( 16 ) is connected to a disinfection tank 17 .

[0032] The top of the electro-flocculation-ozone catalytic oxidation integrated device 10 is provided with an air outlet 9, and the electrode sheet 6 is connected to a power source 8 via a wire.

[0033] The electro-flocculation-ozone catalytic oxidation integrated device 10 is provided with a catalyst 12 therein.

[0034] A water outlet 7 is provided on the outer wall below the catalytic layer of the integrated electro-flocculation-ozone catalytic oxidation device 10 between the ozone generator 14 and the catalyst support layer 13, which is used to flow the effluent of the electro-flocculation catalytic ozone oxidation into the ceramic membrane filtration device through a pipeline, and a mud discharge port 11 is provided at the lower end of the water outlet, which can be opened during the non-operating period to discharge the sludge in the device 10. The ozone generator 14 is arranged in parallel with the integrated electro-flocculation-ozone catalytic oxidation device 10.

[0035] The corresponding processed data in the following Tables 1 to 5 are all recorded after the water quality treatment is stabilized.

[0036] Example 1 The pharmaceutical wastewater is biological fermentation pharmaceutical wastewater.

[0037] The pharmaceutical wastewater is subjected to the following processes: electrocoagulation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process; The parameters of the electrocoagulation process are as follows: the anode is an iron sheet, the cathode is also an iron sheet, the number of electrode pairs is 10, the distance between the electrode plates is 2.0 cm, the plates are placed vertically and parallel, and the current density is controlled at 10 mA / cm 2 .

[0038] The parameters of the ozone catalytic oxidation process are: ozone concentration 40 mg / L, catalyst filling rate 10%, contact time 120 min, and catalyst 12 is manganese dioxide.

[0039] The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 50 nm, the cross-flow velocity is 300 mL / min, the transmembrane pressure difference is 0.2 bar, the pressure difference drives water to pass through the membrane pores, and salts and other soluble organic matter are retained on the membrane surface.

[0040] The reverse osmosis process membrane has a pore size of 0.3 nm and a transmembrane pressure difference of 3.0 bar, and reverse osmosis desalinated fresh water and reverse osmosis concentrated brine are obtained respectively, wherein the reverse osmosis desalinated fresh water is directly reused up to the standard, and the reverse osmosis concentrated brine is returned to the electro-flocculation process for repeated treatment.

[0041] The above pharmaceutical wastewater was tested at each step (the pharmaceutical wastewater after biochemical treatment refers to the water quality after the completion of biochemical treatment and before electrocoagulation treatment), and the results are shown in Table 1.

[0042] From the above, it can be seen that the electro-flocculation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process has a significant removal effect on bio-fermentation pharmaceutical wastewater. This continuous treatment process can effectively remove pollutants in wastewater.

[0043] Example 2 The pharmaceutical wastewater is chemical synthesis pharmaceutical wastewater.

[0044] The pharmaceutical wastewater is subjected to the following processes: electrocoagulation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process; The parameters of the electrocoagulation process are as follows: the anode is an aluminum sheet, the cathode is also an aluminum sheet, the number of electrode pairs is 10, the electrode plate spacing is 1.5 cm, the plates are placed vertically and parallel, and the current density is controlled at 15 mA / cm 2 .

[0045] The parameters of the ozone catalytic oxidation process are: ozone concentration 50 mg / L, catalyst filling rate 20%, contact time 90 min, and catalyst 12 is manganese dioxide.

[0046] The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 40 nm, the cross-flow velocity is 200 mL / min, the transmembrane pressure difference is 0.1 bar, the pressure difference drives water to pass through the membrane pores, and salts and other soluble organic matter are retained on the membrane surface.

[0047] The reverse osmosis process membrane has a pore size of 0.3 nm and a transmembrane pressure difference of 2.0 bar, and reverse osmosis desalinated fresh water and reverse osmosis concentrated brine are obtained respectively, wherein the reverse osmosis desalinated fresh water is directly reused up to the standard, and the reverse osmosis concentrated brine is returned to the electrocoagulation process for repeated treatment.

[0048] The above pharmaceutical wastewater was tested at each step (the pharmaceutical wastewater after biochemical treatment refers to the water quality after the completion of biochemical treatment and before electrocoagulation treatment), and the results are shown in Table 2.

[0049] From the above, it can be seen that the electro-flocculation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process has a significant removal effect on chemical synthesis pharmaceutical wastewater. This continuous treatment process can effectively remove pollutants in wastewater.

[0050] Example 3 The pharmaceutical wastewater is extraction-type pharmaceutical wastewater.

[0051] The pharmaceutical wastewater is subjected to the following processes: electrocoagulation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process; The parameters of the electrocoagulation process are as follows: the anode is a zinc sheet, the cathode is also a zinc sheet, the number of electrode pairs is 10, the distance between the electrode plates is 3.5 cm, the plates are placed vertically and parallel, and the current density is controlled at 20 mA / cm 2 .

[0052] The parameters of the ozone catalytic oxidation process are: ozone concentration 60 mg / L, catalyst filling rate 30%, contact time 100 min, and the catalyst 12 is activated carbon.

[0053] The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 45 nm, the cross-flow velocity is 500 mL / min, the transmembrane pressure difference is 0.3 bar, the pressure difference drives water to pass through the membrane pores, and salts and other soluble organic matter are retained on the membrane surface.

[0054] The reverse osmosis process membrane has a pore size of 0.4 nm and a transmembrane pressure difference of 2.0 bar, and reverse osmosis desalinated fresh water and reverse osmosis concentrated brine are obtained respectively, wherein the reverse osmosis desalinated fresh water is directly reused up to the standard, and the reverse osmosis concentrated brine is returned to the electro-flocculation process for repeated treatment.

[0055] The above pharmaceutical wastewater was tested at each step (the pharmaceutical wastewater after biochemical treatment refers to the water quality after the completion of biochemical treatment and before electrocoagulation treatment), and the results are shown in Table 3.

[0056] From the above, it can be seen that the electro-flocculation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process has a significant removal effect on extraction pharmaceutical wastewater. This continuous treatment process can effectively remove pollutants in wastewater.

[0057] Comparative Example 1 This comparative example is the same as Example 1, except that the electrocoagulation process is removed, and the pharmaceutical wastewater is subjected to the following processes: ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process; The parameters of the ozone catalytic oxidation process are: ozone concentration 40 mg / L, catalyst filling rate 10%, contact time 120 min, and catalyst 12 is manganese dioxide.

[0058] The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 50 nm, the cross-flow velocity is 300 mL / min, the transmembrane pressure difference is 0.2 bar, the pressure difference drives water to pass through the membrane pores, and salts and other soluble organic matter are retained on the membrane surface.

[0059] The reverse osmosis process membrane has a pore size of 0.3 nm and a transmembrane pressure difference of 3.0 bar, and reverse osmosis desalinated fresh water and reverse osmosis concentrated brine are obtained respectively. The reverse osmosis desalinated fresh water is directly reused and meets the standards, and the reverse osmosis concentrated brine is returned to the ozone catalytic oxidation process for repeated treatment.

[0060] The above pharmaceutical wastewater was tested after biochemical treatment, as well as the tests at each step, as shown in Table 4.

[0061] From the above, it can be seen that when the electro-flocculation process is removed, the ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process will affect the overall removal effect of bio-fermentation pharmaceutical wastewater. As a limiting factor in this integrated process, the electro-flocculation process is crucial to the SS and TDS removal efficiency and its promotion to subsequent processes.

[0062] Comparative Example 2 This comparative example is the same as Example 1, except that the ozone catalytic oxidation process is removed, and the pharmaceutical wastewater is subjected to the following processes: electrocoagulation process → ceramic membrane separation process → reverse osmosis process; The parameters of the electrocoagulation process are as follows: the anode is an iron sheet, the cathode is also an iron sheet, the number of electrode pairs is 10, the distance between the electrode plates is 2.0 cm, the plates are placed vertically and parallel, and the current density is controlled at 10 mA / cm 2 .

[0063] The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 50 nm, the cross-flow velocity is 300 mL / min, the transmembrane pressure difference is 0.2 bar, the pressure difference drives water to pass through the membrane pores, and salts and other soluble organic matter are retained on the membrane surface.

[0064] The reverse osmosis process membrane has a pore size of 0.3 nm and a transmembrane pressure difference of 3.0 bar, and reverse osmosis desalinated fresh water and reverse osmosis concentrated brine are obtained respectively, wherein the reverse osmosis desalinated fresh water is directly reused up to the standard, and the reverse osmosis concentrated brine is returned to the electro-flocculation process for repeated treatment.

[0065] The above pharmaceutical wastewater was tested after biochemical treatment, as well as the tests at each step, as shown in Table 5.

[0066] From the above, it can be seen that when the ozone catalytic oxidation process is removed, the electrocoagulation process → ceramic membrane separation process → reverse osmosis process will affect the overall removal effect of bio-fermentation pharmaceutical wastewater. The ozone catalytic oxidation process, as a limiting factor in the integrated process, is crucial to the removal efficiency of COD and ibuprofen and its promotion to subsequent processes.

Claims

1. A pharmaceutical wastewater treatment process, characterized in that: The pharmaceutical wastewater is subjected to the following processes: Electrocoagulation process → ozone catalytic oxidation process → ceramic membrane separation process → reverse osmosis process; The reverse osmosis process has a membrane pore size of 0.3-0.4 nm and a transmembrane pressure difference of 2.0-3.0 bar, and obtains reverse osmosis desalinated fresh water and reverse osmosis concentrated brine respectively, wherein the reverse osmosis desalinated fresh water is directly reused up to the standard, and the reverse osmosis concentrated brine is returned to the electrocoagulation process for repeated treatment.

2. The pharmaceutical wastewater treatment process according to claim 1, characterized in that: The parameters of the electrocoagulation process are as follows: the anode is aluminum sheet, iron sheet or zinc sheet, the cathode is a corresponding metal electrode of the same type, the number of electrode pairs is 10, the distance between the electrode plates is 1.5~3.5cm, and the current density is controlled at 10~20mA / cm 2 .

3. The pharmaceutical wastewater treatment process according to claim 1, characterized in that: The parameters of the ozone catalytic oxidation process are: ozone concentration of 40-60 mg / L, catalyst filling rate of 10-30%, contact time of 90-120 min, and the catalyst is activated carbon or metal oxide.

4. The pharmaceutical wastewater treatment process according to claim 1, characterized in that: The ceramic membrane separation process parameters are as follows: a tubular ceramic membrane is used, the pore size is 40-50 nm, the cross-flow velocity is 200-500 mL / min, and the transmembrane pressure difference is 0.1-0.3 bar.

5. The pharmaceutical wastewater treatment process according to claim 1, characterized in that: The initial SS of the pharmaceutical wastewater is 102-148 mg / L, the initial COD is 212-230 mg / L, and the total dissolved solids is 3800-4400 mg / L.

6. A treatment device used in the pharmaceutical wastewater treatment process according to any one of claims 1 to 5, characterized in that: The invention comprises an integrated electro-flocculation-ozone catalytic oxidation device (10), wherein two electrode sheets (6) are arranged inside the integrated electro-flocculation-ozone catalytic oxidation device (10), an ozone generator (14) is arranged at the bottom of the integrated electro-flocculation-ozone catalytic oxidation device (10), and a catalyst supporting layer (13) is arranged inside the integrated electro-flocculation-ozone catalytic oxidation device (10).

7. The treatment device used in the pharmaceutical wastewater treatment process according to claim 6 is characterized in that: The sewage inlet of the electric flocculation-ozone catalytic oxidation integrated device (10) is connected to a grille (1), the grille (1) is connected to a grit chamber (2), the grit chamber (2) is connected to a primary sedimentation tank (3), the primary sedimentation tank (3) is connected to a biochemical tank (4), the biochemical tank (4) is connected to a secondary sedimentation tank (5), and the secondary sedimentation tank (5) is connected to the electric flocculation-ozone catalytic oxidation integrated device (10).

8. The treatment device used in the pharmaceutical wastewater treatment process according to claim 6 is characterized in that: The water outlet of the integrated electro-flocculation-ozone catalytic oxidation device (10) is connected to a ceramic membrane filtration device (15), the ceramic membrane filtration device (15) is connected to a reverse osmosis device (16), and the reverse osmosis device (16) is connected to a disinfection tank (17).

9. The treatment device used in the pharmaceutical wastewater treatment process according to claim 6 is characterized in that: The top of the electro-flocculation-ozone catalytic oxidation integrated device (10) is provided with an air outlet (9), and the electrode sheet (6) is connected to a power source (8) via a wire.

10. The treatment device used in the pharmaceutical wastewater treatment process according to claim 6 is characterized in that: A water outlet (7) and a mud outlet (11) are provided on the body of the integrated electric flocculation-ozone catalytic oxidation device (10) between the ozone generator (14) and the catalyst support layer (13).

Images